# Elanco Animal Health Inc.

**ELAN**

NYSE; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001739104

**D**

**fourth fifth of 370 graded peers in healthcare**

rank 270 of 370; percentile 72.9; sampling error 2.5 points; lower is stronger


A B C D E

**D, the sloth**




| Scoreboard | |
|---|---|
| **Profitability** | C<br>percentile 43.5 |
| **Solvency** | D<br>percentile 69.0 |
| **Growth and financing** | C<br>percentile 54.8 |
| **Reliability** | 0.94 AUC<br>filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025 |
| **Peer failure rate** | 0.52% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | over $2.67B assets<br>total assets $13.4B |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | none triggered<br>not computable: distress |
| **Inputs computable** | 8 of 14 |
| **Graded from** | filings received through Feb 24, 2026<br>239 days before the rescan; latest periodic filing 10-Q received Aug 5, 2026 |
| **Last close** | $22.68<br>2026-10-20; market equity $11.3B; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Feb 24, 2026*

- Intellectual Property. As the patents for a product expire, competitors may begin to introduce generic or other alternatives, and as a result, we may face competition from lower-priced alternatives to many of our products. Further, generic competitors have sold, and could in the future attempt to market and/or sell, competing products before our patent rights expire. For example, in January 2026, a competitor began selling a generic product competitive to our Seresto collar in the U.S., more than a year before certain relevant patent rights expire.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*


| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 43.5** | | | | | | |
| Gross profitability | 19.4% | 32.3% | | 65.1 | 371 | 2025-12-31 |
| Return on invested capital | not computable | 9.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| Accruals ratio | (6.1%) | (6.6%) | 58.0 | 812 | 2025-12-31 |
| Gross margin stability, five years | 0.7 pts | 2.8 pts | 7.5 | 242 | 2025-12-31 |
| **Solvency, sleeve percentile 69.0** | | | | | |
| Twelve-month failure probability | not computable | 0.06% | | | |
| *latest liabilities, cash plus short-term investments, book equity, and shares are required* | | | | | |
| Altman Z double-prime | not computable | (0.30) | | | |
| *one or more required annual facts are missing* | | | | | |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *one or more required annual facts are missing* | | | | | |
| Interest coverage | not computable | (4.51x) | | | |
| *one or more required annual facts are missing* | | | | | |
| Current ratio | 2.17x | 2.96x | 69.0 | 840 | 2025-12-31 |
| **Growth and financing, sleeve percentile 54.8** | | | | | |
| Revenue growth, three-year compound | 2.2% | 10.1% | 65.6 | 414 | 2025-12-31 |
| Free cash flow growth, three-year compound | 0.4% | 10.9% | 72.6 | 96 | 2025-12-31 |
| Reinvestment rate | not computable | 37.1% | | | |
| *one or more required annual facts are missing* | | | | | |
| Asset growth, three years | (4.8%) | 2.1% | 61.9 | 705 | 2025-12-31 |
| Net share issuance, one year | 0.5% | 2.4% | 18.8 | 633 | 2026-02-19 |

## Among 370 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 265 | Bausch & Lomb Corp. (BLCO) | 71.5 | D | |
| 266 | Pennant Group, Inc. (PNTG) | 71.8 | D | |
| 267 | Cumberland Pharmaceuticals Inc. (CPIX) | 72.1 | D | |
| 268 | Bausch Health Companies Inc. (BHC) | 72.4 | D | |
| 269 | 3M Co. (MMM) | 72.6 | D | |
| 270 | Elanco Animal Health Inc. (ELAN) | 72.9 | D | |
| 271 | Ovid Therapeutics Inc. (OVID) | 73.2 | D | dilution, short runway |
| 272 | ICU Medical Inc/De (ICUI) | 73.4 | D | |
| 273 | Butterfly Network, Inc. (BFLY) | 73.7 | D | |
| 274 | Viatris Inc. (VTRS) | 74.0 | D | |
| 275 | Vir Biotechnology, Inc. (VIR) | 74.3 | D | |

## What the price implies

*at the 2026-10-20 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 18.8% | 8.0% | 58 |
| Distance from 52-week high | (15.4%) | (29.7%) | 69 |
| EBIT to enterprise value | not computable | (1.5%) | |
| Free cash flow yield | 2.5% | (1.0%) | 68 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | |
|---|---|---|---|
| Book value to price | 0.58 | 0.28 | 75 |
| Sales to price | 0.42 | 0.30 | 61 |
| Composite equity issuance, five years | 5.7% | 20.5% | 34 |
| Relative strength against the sector, log excess return | (0.04) | (0.13) | 58 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score 5 of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | pass |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | pass |
| Current ratio improved | fail |
| No new shares issued | fail |
| Gross margin improved | pass |
| Asset turnover improved | pass |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $530.0M |
| Operating cash flow, four quarters | $617.0M |
| Months of runway | not finite |
| Days since last periodic filing | 77 (10-Q received Aug 5, 2026) |
| Median daily dollar volume, 63 sessions | $122.2M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | gross profit | us-gaap:GrossProfit | $2.6B | 2025-12-31 | 2026-02-24 | 10-K | 26-000012 |
| 2 | assets | us-gaap:Assets | $13.4B | 2025-12-31 | 2026-02-24 | 10-K | 26-000012 |
| 3 | net income | us-gaap:NetIncomeLoss | -$232.0M | 2025-12-31 | 2026-02-24 | 10-K | 26-000012 |
| 4 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $560.0M | 2025-12-31 | 2026-02-24 | 10-K | 26-000012 |
| 5 | assets | us-gaap:Assets | $12.6B | 2024-12-31 | 2026-02-24 | 10-K | 26-000012 |
| 6 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $4.7B | 2025-12-31 | 2026-02-24 | 10-K | 26-000012 |
| 7 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $4.4B | 2024-12-31 | 2026-02-24 | 10-K | 26-000012 |
| 8 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $2.0B | 2024-12-31 | 2026-02-24 | 10-K | 26-000012 |
| 9 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $4.4B | 2023-12-31 | 2026-02-24 | 10-K | 26-000012 |
| 10 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $1.9B | 2023-12-31 | 2026-02-24 | 10-K | 26-000012 |
| 11 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $4.4B | 2022-12-31 | 2025-02-25 | 10-K | 25-000014 |
| 12 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $1.9B | 2022-12-31 | 2025-02-25 | 10-K | 25-000014 |
| 13 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $4.8B | 2021-12-31 | 2024-02-26 | 10-K | 24-000009 |
| 14 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $2.1B | 2021-12-31 | 2024-02-26 | 10-K | 24-000009 |
| 15 | current assets | us-gaap:AssetsCurrent | $3.5B | 2025-12-31 | 2026-02-24 | 10-K | 26-000012 |
| 16 | current liabilities | us-gaap:LiabilitiesCurrent | $1.6B | 2025-12-31 | 2026-02-24 | 10-K | 26-000012 |
| 17 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $276.0M | 2025-12-31 | 2026-02-24 | 10-K | 26-000012 |
| 18 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $541.0M | 2024-12-31 | 2026-02-24 | 10-K | 26-000012 |
| 19 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $147.0M | 2024-12-31 | 2026-02-24 | 10-K | 26-000012 |
| 20 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $271.0M | 2023-12-31 | 2026-02-24 | 10-K | 26-000012 |
| 21 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $140.0M | 2023-12-31 | 2026-02-24 | 10-K | 26-000012 |
| 22 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $452.0M | 2022-12-31 | 2025-02-25 | 10-K | 25-000014 |
| 23 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $171.0M | 2022-12-31 | 2025-02-25 | 10-K | 25-000014 |
| 24 | assets | us-gaap:Assets | $14.4B | 2023-12-31 | 2025-02-25 | 10-K | 25-000014 |
| 25 | assets | us-gaap:Assets | $15.5B | 2022-12-31 | 2024-02-26 | 10-K | 24-000009 |
| 26 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 497,168,077 | 2026-02-19 | 2026-02-24 | 10-K | 26-000012 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| 27 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 494,613,940 | 2025-02-20 | 2025-02-25 | 10-K | 25-000014 | |